Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

The mutant JAK2V617F tyrosine kinase (TK) is present in the majority of patients with BCR-ABL–negative myeloproliferative neoplasms (MPNs). JAK2V617F activates downstream signaling through the signal transducers and activators of transcription (STAT), RAS/mitogen-activated protein kinase (MAPK), and...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wang, Yongchao, Fiskus, Warren, Chong, Daniel G., Buckley, Kathleen M., Natarajan, Kavita, Rao, Rekha, Joshi, Atul, Balusu, Ramesh, Koul, Sanjay, Chen, Jianguang, Savoie, Andrew, Ustun, Celalettin, Jillella, Anand P., Atadja, Peter, Levine, Ross L., Bhalla, Kapil N.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2009
Matèries:
Myeloid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2788976/
https://ncbi.nlm.nih.gov/pubmed/19828702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-05-222133
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars